COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Targeting Microvascular Dysfunction in Young Hypertensive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01047423
Recruitment Status : Withdrawn
First Posted : January 12, 2010
Last Update Posted : July 5, 2019
Belfast Health and Social Care Trust
Information provided by (Responsible Party):
Gary E McVeigh, Queen's University, Belfast

Brief Summary:
Cholesterol and blood pressure lowering tablets have been shown to be of benefit in patients with established high blood pressure. High blood pressure is a very common medical condition that can lead to vascular complications i.e. problems with the blood vessels in the body. One way of detecting early changes in these blood vessels as a result of high blood pressure is to measure their compliance/flexibility with a noninvasive technique known as ultrasound and with a simple blood test. The investigators are trying to establish whether these early changes in blood vessels can be significantly improved by the use of both a cholesterol and blood pressure lowering tablet at an earlier stage than is currently advised. The investigators hope that the early combination of these tablets will prove more effective than the use of a blood pressure lowering tablet by itself and therefore possibly reduce the risk of long term complications developing.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Simvastatin Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Targeting Microvascular Dysfunction in Young Hypertensive Patients
Study Start Date : August 2009
Estimated Primary Completion Date : August 2011
Estimated Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Simvastatin

Arm Intervention/treatment
Experimental: Simvastatin
40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
Drug: Simvastatin
40mg encapsulated once daily for 12 weeks

Placebo Comparator: Placebo
Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
Drug: Placebo
Encapsulated oral once daily for 12 weeks

Primary Outcome Measures :
  1. To demonstrate a significant difference in flow-mediated dilatation of the brachial artery and microvasculature between groups. [ Time Frame: 0, 3, 4 and 7 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • To be eligible for the study, all of the following criteria must be met:

    • All patients must have a diagnosis of essential hypertension with off treatment systolic pressure >140 mmHg and/or diastolic pressure >90 mmHg, measured at rest in the seated position on at least two separate occasions, at least 2 weeks apart.
    • Patients will be < 50 years for men and < 60 years for women.
    • Female patients of childbearing potential must be using a medically accepted means of contraception (that is, interuterine device, oral contraceptive, implant, DepoProvera or barrier devices). Female patients of childbearing age will be screened with a pregnancy test.
    • Patients will be typically already on antihypertensive therapy.
    • Patients must have a level of understanding sufficient to complete all tests and examinations required by the protocol and are able to understand and give informed consent.

Exclusion Criteria:

  • Patients will be excluded from the study if they meet any of the following criteria:

    • A history of diabetes mellitus, coronary artery or cerebrovascular disease, hypertensive retinopathy, hypertensive nephropathy, left ventricular hypertrophy or hyperlipidaemia warranting treatment as defined by the latest NICE guidelines which recommend an age based treatment strategy rather than one driven purely by lipid levels in isolation.
    • Abnormal baseline liver function (defined as AST or ALT > 3 times upper limit of normal), raised baseline creatinine kinase (CK) (defined as CK > 200 mmol/L), severe renal impairment (defined as estimated glomerular filtration rate (eGFR) < 30 mls/minute) or previous adverse event relating to either an ARB or statin in the past.
    • Female patients will be excluded if they are pregnant, intend to be pregnant or are lactating. Female patients of childbearing age will be screened with a pregnancy test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01047423

Layout table for location information
United Kingdom
Belfast health and social care trust
Belfast, United Kingdom, BT9 7BL
Sponsors and Collaborators
Queen's University, Belfast
Belfast Health and Social Care Trust
Layout table for investigator information
Principal Investigator: Gary E McVeigh, FRCP PhD Queen's University, Belfast
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Gary E McVeigh, Professor, Queen's University, Belfast Identifier: NCT01047423    
Other Study ID Numbers: 2009‐011638‐90
First Posted: January 12, 2010    Key Record Dates
Last Update Posted: July 5, 2019
Last Verified: July 2019
Keywords provided by Gary E McVeigh, Queen's University, Belfast:
Hypertension endothelial dysfunction statin prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors